Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Orlena Wyatt

Registered Nurse, Gastroenterology Locust Grove, GA Nurse Practitioner

NPI 1851791446 CMS profile 10674125

4865 Bill Gardner Pkwy, Locust Grove, GA 30248

Open in the dashboard

General payments

$5,692

264 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Orlena Wyatt of Locust Grove, GA is reported in the CMS Open Payments database as having received $5,692 across 264 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,374 55
2024 General $1,758 86
2023 General $1,336 58
2022 General $786 34
2021 General $437 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Orlena Wyatt
  • Georgia median
  • Middle half of Georgia
  • National median

In program year 2025, general payments to Orlena Wyatt were reported at $1,374. Among 34,129 Georgia profiles paid that year, the median was $183 and the middle half received between $50 and $656.

Show as a table
Year Orlena Wyatt Georgia median Middle half National median
2019 $0 $177 $54–$648 $163
2020 $0 $130 $38–$432 $114
2021 $437 $141 $38–$499 $132
2022 $786 $164 $45–$574 $149
2023 $1,336 $177 $49–$620 $160
2024 $1,758 $177 $51–$638 $164
2025 $1,374 $183 $50–$656 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,103 100 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $531 27 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $425 24 payments
  4. Intercept Pharmaceuticals, Inc. $321 10 payments
  5. Ardelyx, Inc. $296 14 payments
  6. Regeneron Healthcare Solutions, Inc. $286 11 payments
  7. Genzyme Corporation $215 8 payments
  8. Ipsen Biopharmaceuticals, Inc $159 2 payments
  9. Phathom Pharmaceuticals, Inc. $157 7 payments
  10. Merck Sharp & Dohme Corporation $148 7 payments
  11. Other $1,051 54 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,656 263 payments
  2. Gift $36 1 payment
Products named General payments · program years 2021–2025
  1. RINVOQ $706 26 payments
  2. SKYRIZI $694 26 payments
  3. LINZESS $512 41 payments
  4. CREON $455 35 payments
  5. XIFAXAN $390 22 payments
  6. ENTYVIO $376 19 payments
  7. OCALIVA $307 9 payments
  8. IBSRELA $296 14 payments
  9. DUPIXENT Inflammation And Immunology $224 9 payments
  10. DUPIXENT Immunology $215 8 payments
  11. Other $2,535 128 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,414

Median for Nurse Practitioner: 389

Drug cost

$968,275

Median for Nurse Practitioner: $21,885

Branded share of claims

31.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 25 $665,974
Creon Lipase/Protease/Amylase Brand 40 $108,355
Zenpep Lipase/Protease/Amylase Brand 18 $64,989
Linzess Linaclotide Brand 61 $60,539
Trulance Plecanatide Brand 32 $26,907
Dexlansoprazole Dr Dexlansoprazole Brand 26 $9,728
Mesalamine Er Mesalamine Brand 26 $7,225
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 61 $4,363
Cholestyramine Cholestyramine (With Sugar) Brand 35 $4,017
Pantoprazole Sodium Generic 326 $3,393

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $224
$224 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $162
$162 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $114
$114 — —
LINZESS
  • AbbVie, Inc. $74
  • Ironwood Pharmaceuticals, Inc $32
$107 61 —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $105
$105 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

264 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Registered Nurse, Gastroenterology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record